Cargando…
Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model
BACKGROUND: Scabies is one of the commonest dermatological conditions globally; however it is a largely underexplored and truly neglected infectious disease. Foremost, improvement in the management of this public health burden is imperative. Current treatments with topical agents and/or oral ivermec...
Autores principales: | Bernigaud, Charlotte, Fang, Fang, Fischer, Katja, Lespine, Anne, Aho, Ludwig Serge, Dreau, Dominique, Kelly, Andrew, Sutra, Jean-François, Moreau, Francis, Lilin, Thomas, Botterel, Françoise, Guillot, Jacques, Chosidow, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5061321/ https://www.ncbi.nlm.nih.gov/pubmed/27732588 http://dx.doi.org/10.1371/journal.pntd.0005030 |
Ejemplares similares
-
Prospects for Moxidectin as a New Oral Treatment for Human Scabies
por: Mounsey, Kate E., et al.
Publicado: (2016) -
Relative Neurotoxicity of Ivermectin and Moxidectin in Mdr1ab (−/−) Mice and Effects on Mammalian GABA(A) Channel Activity
por: Ménez, Cécile, et al.
Publicado: (2012) -
A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients
por: Bousquet-Mélou, Alain, et al.
Publicado: (2021) -
High-dose ivermectin in malaria and other parasitic diseases: a new step in the development of a neglected drug
por: Chosidow, Olivier, et al.
Publicado: (2018) -
Ivermectin as a potential treatment for COVID-19?
por: Chosidow, Olivier, et al.
Publicado: (2021)